References
- Azanza Perea JR, Sádaba Díaz de Rada B. Ceftobiprole: pharmacokinetics and PK/PD profile. Rev Esp Quimioter. 2019;32 Suppl 3:11–16.
- Tascini C, Attanasio V, Ripa M, et al. Ceftobiprole for the treatment of infective endocarditis: a case series. J Glob Antimicrob Resist. 2020;20:56–59.
- D'Avolio A, Pensi D, Baietto L, et al. Daptomycin pharmacokinetics and pharmacodynamics in septic and critically ill patients. Drugs. 2016;76(12):1161–1174.
- D'Avolio A, Pensi D, Baietto L, et al. Therapeutic drug monitoring of intracellular anti-infective agents. J Pharm Biomed Anal. 2014;101:183–193.
- Avataneo V, D'Avolio A, Cusato J, et al. LC-MS application for therapeutic drug monitoring in alternative matrices. J Pharm Biomed Anal. 2019;166:40–51.
- Garazzino S, Aprato A, Baietto L, et al. Glycopeptide bone penetration in patients with septic pseudoarthrosis of the tibia. Clin Pharmacokinet. 2008;47(12):793–805.
- Garazzino S, Aprato A, Baietto L, et al. Ceftriaxone bone penetration in patients with septic non-union of the tibia. Int J Infect Dis. 2011;15(6):e415-21–e421.
- Torres A, Mouton JW, Pea F. Pharmacokinetics and dosing of ceftobiprole medocaril for the treatment of hospital- and Community-Acquired pneumonia in different patient populations. Clin Pharmacokinet. 2016;55(12):1507–1520.
- Benvenuto M, Benziger DP, Yankelev S, et al. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother. 2006;50(10):3245–3249.
- Craig WA, Andes DR. In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models. Antimicrob Agents Chemother. 2008;52(10):3492–3496.
- Tascini C, Di Paolo A, Poletti R, et al. Daptomycin concentrations in valve tissue and vegetation in patients with bacterial endocarditis. Antimicrob Agents Chemother. 2013;57(1):601–602.